Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.0220
-0.00480-17.91%
At close: -
Comments
Loading...
Viracta Therapeutics Analyst Ratings and Price Targets | OTC:VIRX | Benzinga
Viracta Therapeutics Inc has a consensus price target of $5.04 based on the ratings of 7 analysts. The high is $11 issued by Oppenheimer on May 23, 2024. The low is $0.25 issued by Rodman & Renshaw on December 27, 2024. The 3 most-recent analyst ratings were released by Rodman & Renshaw, RBC Capital, and Leerink Partners on December 27, 2024, November 14, 2024, and August 16, 2024, respectively. With an average price target of $1.75 between Rodman & Renshaw, RBC Capital, and Leerink Partners, there's an implied 7854.55% upside for Viracta Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Rodman & Renshaw
RBC Capital
Leerink Partners
Oppenheimer
HC Wainwright & Co.
1calculated from analyst ratings
Analyst Ratings for Viracta Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 12/27/2024 | Buy Now | 1036.36% | Rodman & Renshaw | — | $3.5 → $0.25 | Downgrade | Buy → Neutral | Get Alert |
| 11/14/2024 | Buy Now | 8990.91% | RBC Capital | Gregory Renza46% | $4 → $2 | Maintains | Outperform | Get Alert |
| 08/16/2024 | Buy Now | 13536.36% | Leerink Partners | Andrew Berens49% | $5 → $3 | Downgrade | Outperform → Market Perform | Get Alert |
| 08/15/2024 | Buy Now | 18081.82% | RBC Capital | Gregory Renza46% | $6 → $4 | Maintains | Outperform | Get Alert |
| 05/23/2024 | Buy Now | 49900% | Oppenheimer | Hartaj Singh47% | $13 → $11 | Maintains | Outperform | Get Alert |
| 04/17/2024 | Buy Now | 58990.91% | Oppenheimer | Hartaj Singh47% | → $13 | Maintains | Outperform | Get Alert |
| 04/16/2024 | Buy Now | 18081.82% | HC Wainwright & Co. | Robert Burns41% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2024 | Buy Now | 18081.82% | HC Wainwright & Co. | Robert Burns41% | $4 → $4 | Reiterates | Buy → Buy | Get Alert |
| 01/05/2024 | Buy Now | 18081.82% | HC Wainwright & Co. | Robert Burns41% | $10 → $4 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | 27172.73% | RBC Capital | Gregory Renza46% | $7 → $6 | Maintains | Outperform | Get Alert |
| 10/05/2023 | Buy Now | 31718.18% | RBC Capital | Gregory Renza46% | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2023 | Buy Now | 31718.18% | RBC Capital | Gregory Renza46% | → $7 | Reiterates | Outperform → Outperform | Get Alert |
| 08/15/2023 | Buy Now | 22627.27% | SVB Securities | Andrew Berens49% | $10 → $5 | Maintains | Outperform | Get Alert |
| 08/15/2023 | Buy Now | 45354.55% | HC Wainwright & Co. | Robert Burns41% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/31/2023 | Buy Now | 45354.55% | EF Hutton | Tony Butler42% | → $10 | Initiates | → Buy | Get Alert |
| 07/05/2023 | Buy Now | 45354.55% | HC Wainwright & Co. | Robert Burns41% | $33 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 149900% | HC Wainwright & Co. | Robert Burns41% | $35 → $33 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 31718.18% | RBC Capital | Gregory Renza46% | $8 → $7 | Maintains | Outperform | Get Alert |
| 05/08/2023 | Buy Now | 49900% | SVB Securities | Andrew Berens49% | $11 → $11 | Maintains | Outperform | Get Alert |
| 03/27/2023 | Buy Now | 72627.27% | Oppenheimer | Hartaj Singh47% | $14 → $16 | Maintains | Outperform | Get Alert |
| 03/14/2023 | Buy Now | 36263.64% | RBC Capital | Gregory Renza46% | → $8 | Reiterates | → Outperform | Get Alert |
| 03/14/2023 | Buy Now | 158990.91% | HC Wainwright & Co. | Robert Burns41% | → $35 | Reiterates | → Buy | Get Alert |
| 11/11/2022 | Buy Now | 36263.64% | RBC Capital | Gregory Renza46% | $10 → $8 | Maintains | Outperform | Get Alert |
| 11/10/2022 | Buy Now | 49900% | SVB Securities | Andrew Berens49% | → $11 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Viracta Therapeutics (VIRX) stock?
The latest price target for Viracta Therapeutics (OTCPK:VIRX) was reported by Rodman & Renshaw on December 27, 2024. The analyst firm set a price target for $0.25 expecting VIRX to rise to within 12 months (a possible 1036.36% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Viracta Therapeutics (VIRX)?
The latest analyst rating for Viracta Therapeutics (OTCPK:VIRX) was provided by Rodman & Renshaw, and Viracta Therapeutics downgraded their neutral rating.
When was the last upgrade for Viracta Therapeutics (VIRX)?
There is no last upgrade for Viracta Therapeutics
When was the last downgrade for Viracta Therapeutics (VIRX)?
The last downgrade for Viracta Therapeutics Inc happened on December 27, 2024 when Rodman & Renshaw changed their price target from $3.5 to $0.25 for Viracta Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Viracta Therapeutics (VIRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viracta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viracta Therapeutics was filed on December 27, 2024 so you should expect the next rating to be made available sometime around December 27, 2025.
Is the Analyst Rating Viracta Therapeutics (VIRX) correct?
While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a downgraded with a price target of $3.50 to $0.25. The current price Viracta Therapeutics (VIRX) is trading at is $0.02, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.